FAQ on Tonix Pharmaceuticals' Single-Dose Mpox Vaccine Data Presentation at World Vaccine Congress
Summary
Tonix Pharmaceuticals presented promising preclinical data on its single-dose mpox vaccine, TNX-801, at the World Vaccine Congress, showcasing its efficacy in protecting against mpox and rabbitpox with durable protection, aligning with WHO's target profile for global health emergencies.
What did Tonix Pharmaceuticals present at the World Vaccine Congress?
Tonix Pharmaceuticals presented positive preclinical data on its single-dose mpox vaccine candidate, TNX-801, highlighting its efficacy in protecting animals against mpox and rabbitpox with durable protection lasting six months.
Why is TNX-801 significant?
TNX-801 is significant because it offers durable protection against mpox and rabbitpox, aligns with the World Health Organization’s preferred target profile, and has potential for broad application in current and future mpox outbreaks declared as global health emergencies.
How does TNX-801 work?
TNX-801 is a minimally replicative live-virus vaccine that has shown efficacy in protecting animals, including immunocompromised subjects, against mpox and rabbitpox, with protection lasting up to six months.
Who is involved in the development of TNX-801?
Tonix Pharmaceuticals, a fully-integrated biopharmaceutical company, is developing TNX-801. The company focuses on transforming therapies for pain management and modernizing solutions for public health challenges.
When was the data on TNX-801 presented?
The data on TNX-801 was presented at the World Vaccine Congress Washington 2025.
Where can I find more information about Tonix Pharmaceuticals?
More information about Tonix Pharmaceuticals can be found on their website at www.TonixPharma.com or in the company’s newsroom at https://ibn.fm/TNXP.
What are the implications of TNX-801’s success?
The success of TNX-801 could lead to a new, effective vaccine for mpox, addressing a critical need in global health emergencies and offering protection for immunocompromised individuals.
What other products is Tonix Pharmaceuticals developing?
Tonix Pharmaceuticals is also developing TNX-102 SL for fibromyalgia and acute stress reaction, TNX-1300 for cocaine intoxication, and TNX-1500 for preventing allograft rejection and treating autoimmune diseases, among others.
Has TNX-801 received any regulatory designations?
While the content mentions Fast Track designation for TNX-102 SL, it does not specify any regulatory designations for TNX-801.
What is the potential market for TNX-801?
TNX-801 has potential for broad application in current and future mpox outbreaks, especially those declared as global health emergencies, indicating a significant market in public health preparedness and response.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 119894